Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Conditions
- Advanced Breast Carcinoma
- Advanced Endometrial Carcinoma
- Advanced Fallopian Tube Carcinoma
- Advanced Hepatocellular Carcinoma
- Advanced Malignant Abdominal Neoplasm
- Advanced Malignant Female Reproductive System Neoplasm
- Advanced Malignant Thoracic Neoplasm
- Advanced Ovarian Carcinoma
- Advanced Primary Peritoneal Carcinoma
- Advanced Renal Cell Carcinoma
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Malignant Abdominal Neoplasm
- Malignant Solid Neoplasm
- Metastatic Breast Carcinoma
- Metastatic Endometrial Carcinoma
- Metastatic Fallopian Tube Carcinoma
- Metastatic Hepatocellular Carcinoma
- Metastatic Malignant Abdominal Neoplasm
- Metastatic Malignant Female Reproductive System Neoplasm
- Metastatic Malignant Thoracic Neoplasm
- Metastatic Ovarian Carcinoma
- Metastatic Primary Peritoneal Carcinoma
- Metastatic Renal Cell Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Stage III Fallopian Tube Cancer AJCC v8
- Stage III Hepatocellular Carcinoma AJCC v8
- Stage III Ovarian Cancer AJCC v8
- Stage III Primary Peritoneal Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage III Uterine Corpus Cancer AJCC v8
- Stage IIIA Fallopian Tube Cancer AJCC v8
- Stage IIIA Hepatocellular Carcinoma AJCC v8
- Stage IIIA Ovarian Cancer AJCC v8
- Stage IIIA Primary Peritoneal Cancer AJCC v8
- Stage IIIA Uterine Corpus Cancer AJCC v8
- Stage IIIA1 Fallopian Tube Cancer AJCC v8
- Stage IIIA1 Ovarian Cancer AJCC v8
- Stage IIIA2 Fallopian Tube Cancer AJCC v8
- Stage IIIA2 Ovarian Cancer AJCC v8
- Stage IIIB Fallopian Tube Cancer AJCC v8
- Stage IIIB Hepatocellular Carcinoma AJCC v8
- Stage IIIB Ovarian Cancer AJCC v8
- Stage IIIB Primary Peritoneal Cancer AJCC v8
- Stage IIIB Uterine Corpus Cancer AJCC v8
- Stage IIIC Fallopian Tube Cancer AJCC v8
- Stage IIIC Ovarian Cancer AJCC v8
- Stage IIIC Primary Peritoneal Cancer AJCC v8
- Stage IIIC Uterine Corpus Cancer AJCC v8
- Stage IIIC1 Uterine Corpus Cancer AJCC v8
- Stage IIIC2 Uterine Corpus Cancer AJCC v8
- Stage IV Fallopian Tube Cancer AJCC v8
- Stage IV Hepatocellular Carcinoma AJCC v8
- Stage IV Ovarian Cancer AJCC v8
- Stage IV Primary Peritoneal Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Uterine Corpus Cancer AJCC v8
- Stage IVA Fallopian Tube Cancer AJCC v8
- Stage IVA Hepatocellular Carcinoma AJCC v8
- Stage IVA Ovarian Cancer AJCC v8
- Stage IVA Primary Peritoneal Cancer AJCC v8
- Stage IVA Uterine Corpus Cancer AJCC v8
- Stage IVB Fallopian Tube Cancer AJCC v8
- Stage IVB Hepatocellular Carcinoma AJCC v8
- Stage IVB Ovarian Cancer AJCC v8
- Stage IVB Primary Peritoneal Cancer AJCC v8
- Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
- BIOLOGICAL: Atezolizumab
- DRUG: Cabozantinib S-malate
- DRUG: Nab-paclitaxel
- PROCEDURE: Tumor Treating Fields Therapy
Sponsor
M.D. Anderson Cancer Center